Rhythm Pharmaceuticals, Inc. (RYTM)
92.83
-0.58
(-0.62%)
USD |
NASDAQ |
Oct 02, 16:00
92.86
+0.02
(+0.03%)
After-Hours: 20:00
Rhythm Pharmaceuticals Gross Profit Margin (Quarterly) : 87.39% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 87.39% |
| March 31, 2026 | 88.01% |
| December 31, 2025 | 91.61% |
| September 30, 2025 | 89.08% |
| June 30, 2025 | 88.20% |
| March 31, 2025 | 88.33% |
| December 31, 2024 | 90.54% |
| September 30, 2024 | 87.97% |
| June 30, 2024 | 89.26% |
| March 31, 2024 | 88.45% |
| December 31, 2023 | 85.82% |
| Date | Value |
|---|---|
| September 30, 2023 | 88.26% |
| June 30, 2023 | 87.18% |
| March 31, 2023 | 85.49% |
| December 31, 2022 | 85.71% |
| September 30, 2022 | 83.08% |
| June 30, 2022 | 93.38% |
| March 31, 2022 | 69.96% |
| December 31, 2021 | 75.40% |
| September 30, 2021 | 58.85% |
| June 30, 2021 | -24.09% |
| March 31, 2021 | -485.7% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| BioMarin Pharmaceutical, Inc. | 72.27% |
| Cytokinetics, Inc. | 67.78% |
| Exelixis, Inc. | 96.71% |
| Ionis Pharmaceuticals, Inc. | 96.13% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -166.6% |
| Return on Assets | -45.83% |
| Return on Invested Capital | -59.85% |
| Profit Margin (Quarterly) | -69.19% |
| Operating Margin (Quarterly) | -68.14% |
| Return on Net Operating Assets | -296.3% |